How Often Do Patients with ASCVD Achieve Target LDL-C?

A panel of clinical pharmacists introduce themselves and discuss how LDL cholesterol target achievement compares with guideline goals for patients with ASCVD who are treated with maximally tolerated statin monotherapy.

Now Viewing

EP: 1.How Often Do Patients with ASCVD Achieve Target LDL-C?

EP: 2.Gaps Between Guidelines and Clinical Practice Patterns in ASCVD

EP: 3.Comparing the ACC/AHA and ESC/EAS Cholesterol Management Guidelines

EP: 4.Key Barriers in Implementing Guideline-Directed Cholesterol Treatment

EP: 5.Evaluating Non-Statin Lipid-Lowering Therapies in ASCVD

EP: 6.Clinical Efficacy of Non-Statin Treatment Options in ASCVD

EP: 7.Non-Statin Therapies: Cost Effectiveness and Clinical Evidence Gaps

EP: 8.Persistence and Discontinuation Rates for Non-Statin Therapies in ASCVD

EP: 9.The Role of Pharmacists in Treating Very High-Risk ASCVD

EP: 10.Valuable Metrics and Improving Adherence in Patients With ASCVD

EP: 11.Successful Collaborative Care Strategies for Pharmacists

Related Videos

Related Content

Advertisement

December 2nd 2024

Before the Big Event: AI-Enabled Remote Cardiac Monitoring Can Mitigate Stress-Related Cardiovascular Events

Stuart Long

November 27th 2024

Aprocitentan: A New Hope in Resistant Hypertension Management

Kamila Dymala, PharmD, RPh, MBA, BCMTM, PACS

Published: November 27th 2024 | Updated: November 27th 2024

FDA Approves Landiolol For Treatment of Supraventricular Tachycardia

Ashley Gallagher, Associate Editor

November 25th 2024

Acoramidis Received FDA Approval for Treatment of Transthyretin Amyloid Cardiomyopathy

Alexandra Gerlach, Associate Editor

November 25th 2024

β-Blockers: Big Role or Shrinking Spotlight in Cardiovascular Therapy?

Laney Murff, PharmD/BSPS candidate Ron Welch, PharmD, BCPS, BCIDP

November 19th 2024

Abelacimab Reduces Bleeding in AF Patients on Antiplatelet Therapy

Alexandra Gerlach, Associate Editor

Related Content

Advertisement

December 2nd 2024

Before the Big Event: AI-Enabled Remote Cardiac Monitoring Can Mitigate Stress-Related Cardiovascular Events

Stuart Long

November 27th 2024

Aprocitentan: A New Hope in Resistant Hypertension Management

Kamila Dymala, PharmD, RPh, MBA, BCMTM, PACS

Published: November 27th 2024 | Updated: November 27th 2024

FDA Approves Landiolol For Treatment of Supraventricular Tachycardia

Ashley Gallagher, Associate Editor

November 25th 2024

Acoramidis Received FDA Approval for Treatment of Transthyretin Amyloid Cardiomyopathy

Alexandra Gerlach, Associate Editor

November 25th 2024

β-Blockers: Big Role or Shrinking Spotlight in Cardiovascular Therapy?

Laney Murff, PharmD/BSPS candidate Ron Welch, PharmD, BCPS, BCIDP

November 19th 2024

Abelacimab Reduces Bleeding in AF Patients on Antiplatelet Therapy

Alexandra Gerlach, Associate Editor